BridgeMD
Involvement of the serotonergic system in the control of impulsivity in Tourette disorder : ARITEP
EU CTIS ID: 2023-506370-13-00
What this study is testing
To determine the correlative links between the availability of serotonergic 5-HT2A receptors and the variations in impulsivity measured in adults with Tourette's syndrome during treatment begin in the routine care.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or Female
- Diagnosed with a Tourette Disorder following the DSM-5
- Age between 18-65 years
- Member of a social security scheme in France
- Freely-given informed consent to participate to this study (written form)
- With a current treatment by aripiprazole already scheduled
You likely can't join if
- Male or Female
- A serious not controlled psychiatric comorbidity
- A serious, evolving or debilitating pathology with a potential influence on the study
- Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)
- Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)
- Women breastfeeding
See the full eligibility criteria
- Male or Female
- Diagnosed with a Tourette Disorder following the DSM-5
- Age between 18-65 years
- Member of a social security scheme in France
- Freely-given informed consent to participate to this study (written form)
- With a current treatment by aripiprazole already scheduled
- With Tics compatible with TEP/fMRI exams
- Having (for women only) effective contraception throughout participation in the study.
- Male or Female
- A serious not controlled psychiatric comorbidity
- A serious, evolving or debilitating pathology with a potential influence on the study
- Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)
- Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)
- Women breastfeeding
- Protected or restricted person (administratively or in judicial terms)
- Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study
- Do not speak french
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.